- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07572266
Adjuvant Nitrate to Boost Exercise-induced Health Benefits in Older Adults (BOOST-X)
5 août 2026 mis à jour par: Florida Institute for Human and Machine Cognition
Aging-related functional declines are thought to be caused by hallmark biological processes that ultimately manifest in physical, mental, and metabolic impairments to compromise intrinsic capacity and healthspan.
Exercise is the only multipotent treatment with promise to mitigate many of the aging hallmarks, but there is substantial variability in individual exercise responsiveness.
Thus, the investigators approach to boosting exercise responsiveness in aging is to combine an exercise training prescription containing both endurance and resistance training (in alignment with DHHS guidelines) with a nitrate-enriched dietary supplement to augment the cellular, tissue, and systemic adaptations that induce myriad health benefits of exercise in older adults.
Aperçu de l'étude
Statut
Pas encore de recrutement
Les conditions
Description détaillée
Aging-related declines in health and intrinsic capacity are linked to biological processes profoundly affecting all organ systems and tissues including skeletal muscle.
Exercise is a multipotent countermeasure to these processes.
However, there is significant inter-individual response heterogeneity (IRH) in the magnitude of exercise-induced health benefits.
Boosting exercise responsiveness among older adults is thus a top priority.
The investigators have found in older adults that supplementation with nitric oxide (NO) precursors nitrate and nitrite is safe, well tolerated, and improves: (i) physical performance; (ii) vascular endothelial function; (iii) mitochondrial function; (iv) oxidative stress; and (v) muscle inflammation.
The investigators suspect deficits among some older adults in nitrate bioavailability and/or exercise-induced NO production may in part drive suboptimal exercise responsiveness.
Given the powerful and sustaining impact of exercise-induced health benefits on morbidity and mortality, the investigator's fundamental premise is that exercise responsiveness of every older adult should be maximized.
In the BOOST-X Trial the investigators will determine if increasing nitrate bioavailability via dietary supplementation is an efficacious approach to more older adults attaining these essential health benefits.
Low cardiorespiratory fitness (CRF, VO2max) and low functional muscle quality (fMQ; strength/muscle mass) are multi-system manifestations of degenerative aging that include vascular endothelial and mitochondrial dysfunction, oxidative stress, and inflammation.
CRF and fMQ are modifiable with endurance (ET) and resistance (RT) training.
This planned trial will be the first to evaluate the efficacy of coupling a nitrate-rich nutritional supplement with a combined ET+RT prescription in line with DHHS weekly exercise guidelines.
The investigators will test the central hypothesis that daily nitrate supplementation will augment exercise training-induced gains in CRF and fMQ accompanied by improvements in vascular endothelial and mitochondrial function.
Aim 1: Assess the clinical impact of nitrate supplementation on the proportion of older adults attaining exercise-induced health benefits.
N=226 participants stratified by sex and age group (60-69 vs ≥70 y) with random assignment to nitrate (400 mg, 2x/day) (n=113) vs. placebo (nitratedepleted) (n=113) during 12 wk of 3x/wk ET+RT.
1˚ Outcomes: MCID attainment for CRF and fMQ.
Expected Results: Daily nitrate will reduce the proportion of older adults not attaining CRF and fMQ MCIDs by a full 1/3.
Aim 2: Assess potential mechanisms underpinning adaptations to exercise +/- nitrate supplementation.
The investigators will test/integrate in vivo, ex vivo, in vitro and molecular mapping assays considered central to exercise +/- nitrate adaptations and leverage a multidimensional learning framework to better understand the biocircuitry underpinning MCID attainment.
1˚ Outcomes: Vascular endothelial function, muscle mitochondrial function.
Expected Results: MCID attainment will be closely linked to improvements in vascular endothelial function and muscle mitochondrial function.
The acute molecular responses to exercise will be differentially regulated by nitrate supplementation, and the novel biocircuitry will reveal key features that influence adaptability.
Type d'étude
Interventionnel
Inscription (Estimé)
226
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Coordonnées de l'étude
- Nom: Craig Tuggle, MA
- Numéro de téléphone: 850-202-4416
- E-mail: ctuggle@ihmc.org
Lieux d'étude
-
-
Florida
-
Pensacola, Florida, États-Unis, 32502
- Florida Institute for Human and Machine Cognition
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Oui
La description
Inclusion Criteria:
- Male or female aged 60 years or older
- Free of chronic disease or disorder that would preclude full participation or have the potential to confound results
- No structured exercise program (2 or more bouts/wk) within previous 12 months
- Cognitively capable of providing informed consent
Exclusion Criteria:
- BMI ≥ 30.0 kg/m2
- Neurodegenerative disease
- Neuromuscular, musculoskeletal or orthopedic disorder or condition that would limit ability to perform the exercise prescription and/or physical performance testing
- Diagnosed orthostatic hypotension, i.e., a drop in systolic blood pressure of at least 20 mmHg or a drop in diastolic blood pressure of at least 10 mmHg within three minutes of standing up from a sitting or lying position.
- Resting blood pressure <90/60 mmHg or >160/95 mmHg
- Uncontrolled hypertension
- Any current cardiovascular disease or cardiopulmonary instability
Recent cardiovascular event or procedure within the preceding 6 months
- If valve replacement has been performed, patient may not be enrolled for 12 months after the procedure
- Any mechanical valve replacement that requires continuous warfarin anti-coagulation
- Anemia: Hgb <11.0 (♂),10.0 (♂) gm/dl
- Diabetes with HgbA1c >7.0% or fasting blood glucose ≥ 130 mg/dl
- Liver disease with ALT > 52 U/l)
- Chronic kidney disease (eGFR < 45)
- Any current infectious disease
- Any other disease or disorder that could influence exercise response, preclude full participation or have the potential to confound results (e.g., chronic lung disease, cognitive impairment, current cancer diagnosis or within 2 yr remission, cerebrovascular disease, pain)
- Life expectancy < 1 year Medications / lifestyle
- Insulin sensitizing/blood glucose lowering agents such as metformin
- Currently on or have used GLP-1 agonist or other metabolic / weight loss drug in previous 12 weeks
- Use of nitrate medications
- High dose statin (≥40 mg/d simvastatin equivalence)
- Chronic corticosteroids
- Testosterone or other anabolic/androgenic hormone therapy
- Lidocaine allergy
- Regular tobacco use and/or vaping > 1/wk
- Use of cannabis > 1/wk
- Excessive alcohol consumption (3 drinks/d or 7 drinks/wk for females; 4 drinks/d or 14 drinks/wk for males)
- Use of illicit drugs (e.g., cocaine, opioids)
- Unable to commit to ~4 months required to complete the study
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Nitrate Group
Participants will be randomized to an intervention in which they take 800 mg (2 x 400 mg) nitrate-enriched beetroot juice drink [Beet It Sport Nitrate 400 (70 ml per drink)].
Both nitrate and placebo will be purchased from Beet It.
|
Participants will be randomized to an intervention in which they take 800 mg (2 x 400 mg) nitrate-enriched beetroot juice drink [Beet It Sport Nitrate 400 (70 ml per drink)].
Both nitrate and placebo will be purchased from Beet It.
All participants: An exercise dose will be composed of 12 wk of 3d/wk laboratory based supervised prescribed with strategic variations in intensity, volume, and modality across the 3 weekly sessions.
During Monday and Friday RT sessions, participants complete 3 sets x 8-12 reps to volitional fatigue for leg press, knee extension, leg curl, overhead press, lat pulldown or row, and chest press in superset fashion with a 60 s rest between supersets.
On Wednesday, participants perform 2 sets of 13-15 reps of leg press, knee extension, chest press and lat pulldowns with specific cues for speed and fast contractions.
RT is complemented by the ET component which follows a Moderate-High Moderate intensity schedule with 30 min of 70-75% HRR steady state cycling on Monday and Friday separated by a Wednesday 20 min high intensity interval session on a cycle ergometer (1 min on/off; 10 cycles) at near maximal intensity with a target of 90% HRR.
|
|
Comparateur placebo: Placebo Group
Participants will be randomized to an intervention in which they take 800 mg (2 x 400 mg) nitrate-deprived, manufacturer-matched beetroot juice drink [Beet It Sport Nitrate 400 (70 ml per drink)].
Both nitrate and placebo will be purchased from Beet It.
|
All participants: An exercise dose will be composed of 12 wk of 3d/wk laboratory based supervised prescribed with strategic variations in intensity, volume, and modality across the 3 weekly sessions.
During Monday and Friday RT sessions, participants complete 3 sets x 8-12 reps to volitional fatigue for leg press, knee extension, leg curl, overhead press, lat pulldown or row, and chest press in superset fashion with a 60 s rest between supersets.
On Wednesday, participants perform 2 sets of 13-15 reps of leg press, knee extension, chest press and lat pulldowns with specific cues for speed and fast contractions.
RT is complemented by the ET component which follows a Moderate-High Moderate intensity schedule with 30 min of 70-75% HRR steady state cycling on Monday and Friday separated by a Wednesday 20 min high intensity interval session on a cycle ergometer (1 min on/off; 10 cycles) at near maximal intensity with a target of 90% HRR.
Manufacturer-matched placebo that is nitrate-depleted beetroot juice (70 ml per drink).
Both nitrate and placebo will be purchased from Beet It.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Assess the clinical impact of nitrate supplementation on a proportion of older adults attaining exercise-induced health benefits.
Délai: 12 weeks
|
The primary outcome will be assessed using logistic regression with the proportion not attaining Cardiorespiratory Fitness and functional Muscle Quality Minimally Clinical Differences as the response variable and treatment adjusted for sex and age group across the 12 week intervention.
|
12 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Cardiorespiratory demand during submaximal cycle exercise.
Délai: 12 weeks
|
Supportive analyses will include secondary (cardiorespiratory demand during submaximal steady state exercise) outcomes.
The steady state exercise cycling will be 10 minutes at 60% of peak power (Watts) during the VO2 peak test.
|
12 weeks
|
|
Neuromuscular fatiguability during isometric holds.
Délai: 12 weeks
|
The knee extensors will perform a 30 second isometric flexion on a dynamometer.
The fatigue will be defined by the force decline across the 30 seconds.
|
12 weeks
|
|
10 meter max gait speed.
Délai: 12 weeks
|
Participants will walk as quickly as possible across a 10 meter, straight course.
Time is recorded for up to three attempts.
A lower time indicates a faster speed.
|
12 weeks
|
|
modified Balance Error Scoring System (mBESS)
Délai: 12 weeks
|
Stability is assessed with the Sway Medical tablet app via three stances: double-leg, single-leg, and tandem.
Scoring is decided by losing balance or opening eyes during closed eyed tests.
|
12 weeks
|
|
NIH PROMIS Physical Function SF
Délai: 12 weeks
|
The NIH PROMIS Physical Function Short Form (SF) is a standardized tool used to evaluate an individual's physical abilities and limitations in daily activities.
It is part of the broader Patient-Reported Outcomes Measurement Information System (PROMIS), which focuses on measuring patient-reported outcomes across various health domains.
|
12 weeks
|
|
NIH PROMIS Fatigue SF
Délai: 12 weeks
|
PROMIS Fatigue SF refers to the short form of the Patient-Reported Outcomes Measurement Information System designed to assess fatigue levels in patients.
It provides a standardized way to measure fatigue, which can be used in various clinical settings to evaluate patient health status.
|
12 weeks
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Cognitive function.
Délai: 12 weeks
|
Cognitive function is assessed via Sway Medical reaction time via three assessments: visual processing speed: measures how quickly a person can interpret visual information.
|
12 weeks
|
|
Psychological state.
Délai: 12 weeks
|
Depression and anxiety are assessed via the well-validated Patient Health Questionnaire 9 (PHQ-9) both via Sway.
The PHQ-9, or Patient Health Questionnaire-9, is a tool used to screen for, diagnose, and measure the severity of depression.
It consists of nine questions that assess how often a person has experienced symptoms of depression over the past two weeks.
|
12 weeks
|
|
Sleep quality and nocturnal stress.
Délai: 12 weeks
|
Perceptions of sleep quality are measured using the short forms (SF) of PROMIS Sleep Disturbance and Sleep-Related Impairment.
For direct monitoring, participants wear an Oura Gen-4 ring to quantify sleep behavior with stress monitored via Heart Rate /Heart Rate variability (HRV) across the full enrollment period, as we have done in previous studies including the ongoing NIA M3AX Trial (NCT06507189).
The Oura ring is well validated against polysomnography for several sleep metrics and nocturnal HR/HRV.
|
12 weeks
|
|
Free-living activity via the Oura Gen 4.
Délai: 12 weeks
|
Free-living activity is also monitored daily via the Oura Gen-4 ring worn throughout trial participation.
Variables such as step count and heart rate will used to determine activity.
|
12 weeks
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Estimé)
1 novembre 2026
Achèvement primaire (Estimé)
1 mai 2031
Achèvement de l'étude (Estimé)
1 mai 2031
Dates d'inscription aux études
Première soumission
17 avril 2026
Première soumission répondant aux critères de contrôle qualité
30 avril 2026
Première publication (Réel)
7 mai 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
10 août 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
5 août 2026
Dernière vérification
1 avril 2026
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- IRB-2026-0019
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
OUI
Description du régime IPD
De-identified phenotyping data will be made accessible through supplementary data tables and files alongside manuscript publication or via third-party repositories.
This data will also be hosted on secure server space without any link to PHI and made accessible through a publicly available Shiny app.
Primary cell aliquots and biobanked snap frozen muscle and/or frozen blood samples will be provided to investigators upon reasonable request along with de-identified metadata.
Délai de partage IPD
Data share will begin when as soon as first data collections begin.
Sub award sites will enter participant data on the secure Data Entry Management System (DEMS).
Data shares will continue until the close of study.
Critères d'accès au partage IPD
Access to all study data is granted on the researcher regulatory training and local IRB approval.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .